NCT05794321View on ClinicalTrials.gov

Investigating the Use of Intravenous Tranexamic Acid in Gender Affirming Mastectomy

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

September 28, 2023

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Postoperative HematomaPostoperative Seroma
Interventions
DRUG

Intravenous TXA

Patients in the experimental group will receive a loading dose of tranexamic acid (TXA) at a concentration of 1g/10ml over a period of 10 minutes, administered immediately following anesthesia induction.

Trial Locations (1)

94131

RECRUITING

UCSF Department of Plastic & Reconstructive Surgery, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER